Transdermal Delivery of PTEN mRNA via Hyaluronated Lipid Nanoparticles for Melanoma Immunotherapy

Study Background and Research Question

Melanoma remains the most aggressive and treatment-resistant form of skin cancer, notorious for its high metastatic capacity and frequent development of resistance to immune checkpoint inhibitors (ICIs). A key molecular driver of these challenges is the loss or mutation of the tumor suppressor gene phosphatase and tensin homolog (PTEN). PTEN inactivation not only enhances tumor proliferation and metastasis but also impairs T cell infiltration and immune-mediated tumor clearance, undermining the efficacy of immunotherapies. Previous attempts to restore PTEN function using DNA vectors, viral systems, or recombinant proteins have faced significant hurdles, such as genomic integration risks, immunogenicity, and poor cytosolic delivery. This context prompted the question: can an advanced, non-viral mRNA delivery system restore PTEN activity in situ, reactivate antitumor immunity, and inhibit melanoma progression through a topical, transdermal route?

Key Innovation from the Reference Study

The reference study presents a novel hyaluronate-conjugated lipid nanoparticle (HA-LNP) system designed for the transdermal delivery of PTEN mRNA. The innovation lies in the use of HA-dimyristoyl glycerol (HA-DMG), an amphiphilic lipid that incorporates hyaluronate directly into the LNP bilayer during self-assembly. This approach eliminates the need for post-formulation HA coating and avoids the use of poly(ethylene glycol) (PEG), which is associated with immunogenicity and possible anaphylactic reactions. The resulting HA-LNPs display HA moieties on their surface, enabling efficient skin penetration and selective targeting of CD44-expressing tumor cells while maintaining particle stability and biocompatibility. This design supports a scalable, clinically relevant platform for mRNA-based cancer immunotherapy without the drawbacks of PEG-based systems.

Methods and Experimental Design Insights

The study employed a multidisciplinary approach combining materials engineering, molecular biology, and cancer immunology. The HA-LNPs were synthesized using a self-assembly process that incorporated HA-DMG into the lipid bilayer, ensuring HA surface exposure for CD44-mediated cellular targeting. PTEN mRNA, chemically optimized for stability and translation, was encapsulated within these nanoparticles. Key experimental steps included:

• Characterization of HA-LNP size, morphology, and surface charge to confirm nanoparticle uniformity and HA display.
• In vitro evaluation of PTEN mRNA delivery to melanoma cell lines, with assessment of PTEN protein restoration, cell viability, and induction of immunogenic cell death (ICD).
• In vivo studies involving transdermal application of PTEN mRNA@HA-LNPs in a melanoma mouse model, monitoring skin/tumor penetration, tumor growth, immune activation, and toxicity.

Control formulations included conventional PEG-LNPs and unmodified LNPs to benchmark the performance of the HA-LNP system.

Protocol Parameters

• HA-DMG incorporation: Directly integrated into the LNP bilayer during self-assembly for stable HA presentation and particle uniformity.
• PTEN mRNA design: Chemically modified for enhanced stability and suppression of RNA-mediated innate immune activation; capped at the 5' end to mimic endogenous mRNA structure.
• Transdermal application: Topical administration to tumor-bearing mice enables deep skin penetration and targeting of CD44-positive tumor cells.
• Assessment endpoints: PTEN protein expression, immunogenic cell death markers, tumor growth inhibition, immune cell infiltration, and systemic toxicity.

Core Findings and Why They Matter

HA-LNPs loaded with PTEN mRNA demonstrated several critical advances over conventional delivery platforms:

• Efficient skin and tumor penetration: The HA modification facilitated deep dermal and tumor infiltration after topical application, attributed to HA-CD44 interactions and hydration effects.
• Restoration of PTEN expression: PTEN mRNA@HA-LNPs successfully reinstated PTEN protein levels in melanoma cells, reversing the tumor-promoting consequences of PTEN loss.
• Induction of immunogenic cell death: Treated tumor cells exhibited ICD markers, suggesting that restored PTEN expression synergizes with immune activation to enhance tumor clearance.
• Tumor growth inhibition with minimal toxicity: In vivo, the system led to significant tumor regression and increased immune infiltration, with negligible off-target or systemic effects.
• PEG-free, biocompatible design: Replacing PEG-lipids with HA-DMG improved biocompatibility and reduced the risk of immunogenicity, supporting translational potential.

Collectively, these outcomes establish HA-LNPs as a promising vehicle for localized, mRNA-based cancer immunotherapy and offer a blueprint for future non-invasive gene delivery strategies.

Comparison with Existing Internal Articles

While the reference study demonstrates therapeutic mRNA delivery for cancer, several internal articles focus on quantitative mRNA delivery and translation efficiency assays using synthetic reporter mRNAs such as EZ Cap™ Cy5 EGFP mRNA (5-moUTP). These reporter systems, featuring dual fluorescence and immune-evasive modifications, enable real-time tracking of both mRNA uptake and functional protein expression in various delivery vehicles, including nanoparticles, and are widely used for nanoparticle optimization and workflow validation. For example, the internal article "EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Optimizing Dual-Reporter mRNA Delivery" highlights the ability of Cy5-labeled mRNA to benchmark delivery efficiency and translation in vitro and in vivo, streamlining the development of advanced gene regulation and function studies. Similarly, the article "Bicontinuous Nanostructures in CART-Based mRNA Delivery Systems" explores how nanoparticle internal architecture influences mRNA encapsulation and release, offering additional design perspectives relevant to HA-LNP development. Together, these resources illustrate how validated reporter mRNAs complement the therapeutic mRNA approaches demonstrated in the reference study, providing essential tools for preclinical workflow optimization and quality control.

Limitations and Transferability

Despite promising results, several limitations must be recognized:

• Model specificity: The experiments were primarily conducted in melanoma models; efficacy and safety in other cancer types or in human skin remain to be established.
• Translational hurdles: While HA-LNPs are designed for clinical scalability, manufacturing consistency and long-term stability require further validation.
• Immune context: The tumor microenvironment in humans may present additional barriers to mRNA delivery and immune activation not fully captured in murine models.
• Payload generalizability: Although the strategy is demonstrated with PTEN mRNA, adaptation to other therapeutic targets or co-delivery regimens would benefit from additional workflow benchmarking, potentially using dual-reporter mRNA systems for quantitative assessment of delivery and translation.

Research Support Resources

To facilitate the development and validation of advanced mRNA delivery systems, researchers can leverage synthetic dual-reporter mRNAs such as EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011). This Cy5-labeled mRNA combines 5-methoxyuridine modification for immune evasion, a Cap1 structure for enhanced translation, and dual fluorescence for simultaneous tracking of uptake and protein expression. Such tools are valuable for quantitative mRNA delivery and translation efficiency assays, nanoparticle optimization, and gene regulation studies. For detailed experimental scenarios and optimization tips, see related internal analyses (article 1, article 2). Utilization of advanced reporter systems can help bridge the gap between nanoparticle design and therapeutic mRNA application as exemplified in the reference study.